vs
Side-by-side financial comparison of Bilibili Inc. (BILI) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.3B, roughly 1.9× Bilibili Inc.). Zoetis runs the higher net margin — 25.3% vs 6.0%, a 19.3% gap on every dollar of revenue. On growth, Bilibili Inc. posted the faster year-over-year revenue change (26.2% vs 3.0%). Over the past eight quarters, Bilibili Inc.'s revenue compounded faster (27.3% CAGR vs 4.4%).
Bilibili, nicknamed B Site, is a Chinese online video sharing website based in Shanghai where users can submit, view, and add overlaid commentary on videos.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
BILI vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $2.4B |
| Net Profit | $75.7M | $603.0M |
| Gross Margin | 37.0% | 70.2% |
| Operating Margin | 5.8% | 31.9% |
| Net Margin | 6.0% | 25.3% |
| Revenue YoY | 26.2% | 3.0% |
| Net Profit YoY | 143.0% | 3.8% |
| EPS (diluted) | $1.14 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3B | $2.4B | ||
| Q3 25 | $1.1B | $2.4B | ||
| Q2 25 | $1.0B | $2.5B | ||
| Q1 25 | $965.1M | $2.2B | ||
| Q4 24 | $1.0B | $2.3B | ||
| Q3 24 | $1.0B | $2.4B | ||
| Q2 24 | $843.1M | $2.4B | ||
| Q1 24 | $784.5M | $2.2B |
| Q4 25 | $75.7M | $603.0M | ||
| Q3 25 | $65.9M | $721.0M | ||
| Q2 25 | $30.5M | $718.0M | ||
| Q1 25 | $-1.5M | $631.0M | ||
| Q4 24 | $-176.0M | $581.0M | ||
| Q3 24 | $11.4M | $682.0M | ||
| Q2 24 | $83.7M | $624.0M | ||
| Q1 24 | $-105.9M | $599.0M |
| Q4 25 | 37.0% | 70.2% | ||
| Q3 25 | 36.7% | 71.5% | ||
| Q2 25 | 36.5% | 73.6% | ||
| Q1 25 | 36.3% | 72.0% | ||
| Q4 24 | 36.2% | 69.5% | ||
| Q3 24 | 34.9% | 70.6% | ||
| Q2 24 | 29.9% | 71.7% | ||
| Q1 24 | 28.3% | 70.6% |
| Q4 25 | 5.8% | 31.9% | ||
| Q3 25 | 4.6% | 37.0% | ||
| Q2 25 | 3.4% | 36.7% | ||
| Q1 25 | 0.2% | 36.5% | ||
| Q4 24 | -16.0% | 31.6% | ||
| Q3 24 | 0.9% | 36.6% | ||
| Q2 24 | 9.5% | 33.0% | ||
| Q1 24 | -14.5% | 34.1% |
| Q4 25 | 6.0% | 25.3% | ||
| Q3 25 | 6.1% | 30.0% | ||
| Q2 25 | 3.0% | 29.2% | ||
| Q1 25 | -0.2% | 28.4% | ||
| Q4 24 | -17.5% | 25.1% | ||
| Q3 24 | 1.1% | 28.6% | ||
| Q2 24 | 9.9% | 26.4% | ||
| Q1 24 | -13.5% | 27.4% |
| Q4 25 | $1.14 | $1.37 | ||
| Q3 25 | $1.05 | $1.63 | ||
| Q2 25 | $0.51 | $1.61 | ||
| Q1 25 | $0.00 | $1.41 | ||
| Q4 24 | $0.21 | $1.29 | ||
| Q3 24 | $-0.03 | $1.50 | ||
| Q2 24 | $-0.20 | $1.37 | ||
| Q1 24 | $-1.80 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.7B | — |
| Total DebtLower is stronger | $1.4B | — |
| Stockholders' EquityBook value | $2.2B | $3.3B |
| Total Assets | $5.9B | $15.5B |
| Debt / EquityLower = less leverage | 0.62× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.4B | $2.1B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | $1.9B | $1.7B | ||
| Q4 24 | $1.8B | $2.0B | ||
| Q3 24 | $11.7B | $1.7B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | $1.1B | $2.0B |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $700.3M | — | ||
| Q4 24 | $662.5M | — | ||
| Q3 24 | $4.3B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $684.5M | — |
| Q4 25 | $2.2B | $3.3B | ||
| Q3 25 | $2.1B | $5.4B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | $2.0B | $4.7B | ||
| Q4 24 | $1.9B | $4.8B | ||
| Q3 24 | $13.7B | $5.2B | ||
| Q2 24 | — | $5.0B | ||
| Q1 24 | $1.9B | $5.1B |
| Q4 25 | $5.9B | $15.5B | ||
| Q3 25 | $5.6B | $15.2B | ||
| Q2 25 | — | $14.5B | ||
| Q1 25 | $4.6B | $14.1B | ||
| Q4 24 | $4.5B | $14.2B | ||
| Q3 24 | $32.0B | $14.4B | ||
| Q2 24 | — | $14.2B | ||
| Q1 24 | $4.2B | $14.3B |
| Q4 25 | 0.62× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.35× | — | ||
| Q4 24 | 0.34× | — | ||
| Q3 24 | 0.31× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $263.1M | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | 3.47× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $263.1M | $893.0M | ||
| Q3 25 | $283.2M | $938.0M | ||
| Q2 25 | $277.7M | $486.0M | ||
| Q1 25 | $179.4M | $587.0M | ||
| Q4 24 | $191.9M | $905.0M | ||
| Q3 24 | $2.2B | $951.0M | ||
| Q2 24 | — | $502.0M | ||
| Q1 24 | $88.3M | $595.0M |
| Q4 25 | — | $732.0M | ||
| Q3 25 | — | $805.0M | ||
| Q2 25 | — | $308.0M | ||
| Q1 25 | $174.5M | $438.0M | ||
| Q4 24 | — | $689.0M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $370.0M | ||
| Q1 24 | — | $455.0M |
| Q4 25 | — | 30.7% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 12.5% | ||
| Q1 25 | 18.1% | 19.7% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | — | 32.8% | ||
| Q2 24 | — | 15.7% | ||
| Q1 24 | — | 20.8% |
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 7.2% | ||
| Q1 25 | 0.5% | 6.7% | ||
| Q4 24 | — | 9.3% | ||
| Q3 24 | — | 7.0% | ||
| Q2 24 | — | 5.6% | ||
| Q1 24 | — | 6.4% |
| Q4 25 | 3.47× | 1.48× | ||
| Q3 25 | 4.30× | 1.30× | ||
| Q2 25 | 9.11× | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 195.23× | 1.39× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | — | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BILI
| Value-added services (VAS) | $466.4M | 37% |
| Advertising | $435.0M | 34% |
| Mobile games | $220.3M | 17% |
| Other | $80.8M | 6% |
| IP derivatives and others | $68.2M | 5% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
